BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502001-15-00

Acronym

LT3001-205

Enrollment

Registered

2023-09-04

Start date

2023-12-05

Completion date

2025-05-23

Last updated

2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke (AIS)

Brief summary

The proportion of subjects with Adverse Events (AEs), judged to be probably or definitely related to the investigational product (IP) within 90 days after the 1st IP administration.

Interventions

DRUGPlacebo

DRUGLT3001 Drug Product

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The proportion of subjects with Adverse Events (AEs), judged to be probably or definitely related to the investigational product (IP) within 90 days after the 1st IP administration.	—

Countries

Czechia, Germany, Greece, Italy, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026